Crossbow Therapeutics closed a $77 million Series B co‑led by Taiho Ventures and Arkin BioCapital to advance next‑generation T‑cell engagers into the clinic. The financing will support the Phase 1 program of lead candidate CBX‑250—a TCR‑mimetic engager developed with MD Anderson—and preclinical development of a second program, CBX‑663, targeting telomerase peptides expressed across cancers. In preclinical studies Crossbow reports potent tumor cell killing with reduced off‑tumor activity; the company began patient recruitment for an early trial in hematologic malignancies with expected initial readouts by end of 2026. Investors in the round included strategic backers such as Pfizer Ventures. The raise underscores sustained investor appetite for T‑cell engager platforms positioned as off‑the‑shelf alternatives to autologous cell therapies, with emphasis on specificity and safety engineering to mitigate immune‑related toxicities.